Cryolife (CRY) received a Hold rating from Needham analyst Michael Matson today. The company’s shares opened today at $28.97.
Matson commented:
“CRY has undergone a transition into a higher growth company with two major acquisitions since 2015. We believe that it has a full pipeline including 13 new products and indications but we don’t expect these to begin to translate to stronger revenue growth until 2020. And 2019 appears to be a transition year from an earnings and margin perspective. Given all of this, and our belief that CRY shares are fairly valued, we initiate coverage with a Hold rating.”
According to TipRanks.com, Matson is a top 100 analyst with an average return of 13.9% and a 69.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
Cryolife has an analyst consensus of Moderate Buy, with a price target consensus of $32.
See today’s analyst top recommended stocks >>
Based on Cryolife’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $1.74 million. In comparison, last year the company had a GAAP net loss of $3.01 million.
Based on the recent corporate insider activity of 88 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments.
